Are Peptides Legal?

The short answer to “are peptides legal” in the US: some are, and many popular wellness peptides are not. FDA-approved peptide drugs, including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, tesamorelin and bremelanotide, are legal with a prescription. Wellness peptides such as BPC-157, TB-500 and KPV are not approved, and as of September 26, 2026 they still cannot be lawfully compounded. In July 2026 the FDA’s Pharmacy Compounding Advisory Committee voted to recommend six of them for the compounding list, but that vote was advisory and changed no law. Selling any peptide “for research use only” to people who inject it is illegal, and two sellers drew federal prison time this summer.

Current as of September 26, 2026. This is a regulatory summary for operators, not legal advice.

Are peptides legal in the US? The answer by category

“Peptide” is a chemistry term, not a legal one. FDA’s rules treat a chain of more than 40 amino acids as a protein, regulated as a biologic, so peptide medicines of 40 or fewer amino acids are regulated as drugs. From there the law cares about the pathway: which molecule, prescribed by whom, made where, sold how. Every peptide sold as a medicine lands in one of three buckets: an FDA-approved drug, a drug compounded by a licensed pharmacy under section 503A or 503B of the FD&C Act, or a “research use only” product, which is an unapproved drug with a disclaimer taped to it.

Which peptides are FDA approved?

These have a clean answer: legal with a prescription. The table lists what each product is FDA-approved for.

Insulin, at 51 amino acids, is legal by prescription but regulated as a biologic. The list keeps growing: FDA approved the Wegovy pill on December 22, 2025, and the first generic Victoza and Saxenda in December 2024 and August 2025.

Approval attaches to a specific product, not to the molecule. FDA’s August 2026 warning letters treat semaglutide, tirzepatide, tesamorelin and PT-141 sold as “research” products as unapproved new drugs, even though the branded versions are legal. Retatrutide is not approved for anything, and Lilly does not plan to file until 2027.

The July 2026 FDA advisory committee vote on peptides

The panel that voted is FDA’s own Pharmacy Compounding Advisory Committee (PCAC). It is an FDA advisory committee, not a separate health board, and it advises the FDA Commissioner on compounding. The committee met July 23 and 24, 2026 to decide whether to recommend seven peptides for the 503A bulks list, the list that lets a pharmacy compound from an ingredient with no approved drug or USP monograph behind it.

The road there was short and political. FDA had flagged these peptides as potential significant safety risks in September 2023. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. told Joe Rogan he was a “big fan” of peptides (Orrick). On April 15, FDA announced it would pull 12 peptides out of Category 2 after their nominators withdrew them, a change that did not make them compoundable. In June, Kennedy appointed new committee members, including prominent peptide supporters.

FDA’s own scientists opposed every peptide. The briefing document proposed listing none of the 14 forms under review. FDA found BPC-157 poorly characterized and backed by only five small, short human studies, one of them a two-week ulcerative colitis trial that gave the peptide as an enema. It found no patient-use literature for TB-500, no human data for KPV and only lab and rodent data for MOTS-c. Russell Wesdyk of FDA’s Office of Pharmaceutical Quality put it plainly: “We can’t create quality standards until we actually know what it is” (NPR).

The committee voted yes on six anyway.

FDA has posted no official results, so these tallies come from press and law-firm reports; CBS had MOTS-c at 8-6 and RAPS had Epitalon at 7-5-1. The panel itself drew scrutiny. NPR reported that most of the eight members appointed before the meeting have peptide-industry ties, and ABC News reported that six of them run clinics offering peptides. HHS said every member underwent the same ethics review and vetting required of all FDA advisory committee members (PharmExec). Hims & Hers stock rose more than 10% after the BPC-157 vote.

None of it binds FDA. Advisory committees make “non-binding recommendations,” per the agency’s meeting page, and FDA will not issue a final determination until its own review is done. Matthew Lash, acting director of FDA’s Office of Compounding Quality and Compliance, described listing as the “first time creating legal access”, not a restoration.

What has happened since the vote

Legally, nothing. As of September 26, 2026, FDA has published no proposed rule to add the six. The bulks list at 21 CFR 216.23 still names six substances, none a peptide, and FDA’s category list still reads “Updated May 14, 2026.” A separate 503A bulks rule is targeted for November 2026, but it finalizes a 2019 proposal and does not cover peptides.

Lawyers and pharmacy groups agree. Mintz wrote that nothing had legally changed, NCPA told pharmacies they cannot compound the six until final rulemaking is in place, and Holland & Knight said only rulemaking or Congress can change their status.

Meanwhile, President Trump nominated Dr. Heidi Overton as FDA commissioner on August 19. Her Senate hearing was September 24, and Kyle Diamantas remains acting commissioner. Hims & Hers CEO Andrew Dudum said the company is building a peptides offering and would launch if FDA allows compounding. The science has not moved: a UCLA review published in August covered 565 studies of BPC-157, TB-500 and four other popular compounds, found more than two-thirds were animal-only, and found essentially no studies showing significant clinical benefit for musculoskeletal conditions.

What stays illegal: research-use-only sellers

Selling vials online “for research use only” to people who inject them is still the fastest way to break the law with peptides. FDA treats these products as unapproved new drugs and judges intended use from the whole storefront: Sheppard Mullin notes the August letters cited bacteriostatic water, dosing guides and peptide calculators. McDermott says the July vote does not affect these products.

None of the August letters names BPC-157 or the other five recommended peptides, and McDermott calls enforcement against them unsettled. The prison sentences are settled. On July 30, 2026, Matthew Kawa, owner of an online peptide store, got 70 months in the Northern District of Indiana for selling peptides, hCG and SARMs, BPC-157 among them, to an estimated 54,000 customers (CBS News). A week earlier, Brandon Piper got 21 months in the Western District of Michigan for conspiring to sell misbranded drugs, including peptides imported from China and sold “for research purposes only” without prescriptions (CBS Detroit). Eli Lilly has also filed six lawsuits against retatrutide sellers.

State boards are closing the clinic side. Ohio’s pharmacy board bars clinics and med spas from possessing research-grade drugs even with patient consent and, as of December 2025, had summarily suspended more than 30 clinics and med spas for various violations since the start of that year. Alabama (notice, May 26, 2026), Mississippi (August 19, 2026) and South Carolina (notice) have told licensees not to use research-grade peptides. Louisiana’s Act 374 shields peptide prescribing from board discipline, but only for peptides compounded under federal 503A or 503B rules.

FDA compounding regulations for peptides

A 503A pharmacy compounds for an identified patient on a valid prescription, exempt from new-drug approval, but only from a qualifying ingredient: one with a USP or NF monograph, one that is a component of an approved drug, or one on the 503A bulks list. That list holds Brilliant Blue G and five topical-only substances. While FDA reviews nominations, it tolerates compounding with Category 1 substances and would consider enforcement for Category 2. Kisspeptin-10 is the only peptide left in Category 2. Outsourcing facilities under 503B use a separate list based on clinical need, and FDA has not said whether the PCAC peptides will get a 503B review.

FDA issued no formal guidance on compounding peptides in February 2026, and its policies page lists none. The February peptide news was Secretary Kennedy’s February 27 podcast remarks, covered above. On February 6, FDA also issued a press announcement on GLP-1s: FDA said it would restrict GLP-1 ingredients used in mass-marketed compounded drugs, named Hims & Hers, barred claims that compounded versions are generic or the same as approved drugs, and warned of seizure and injunction. On March 3 it warned 30 telehealth companies over compounded GLP-1 marketing.

The semaglutide and tirzepatide shortages are over, and the 503A grace periods ended by April 2025. What remains is FDA’s “essentially a copy” test: same ingredient, similar strength, same route, unless the prescriber documents a significant difference for the patient. On September 18, 2026, FDA told one pharmacy that the volume of its tirzepatide and semaglutide combination products “suggests” its claimed differences from approved drugs “are pretextual,” which Frier Levitt says appears to be a first for GLP-1 co-formulations.

Watch the copy, too. Federal rules say that calling a drug compounded from a listed substance FDA-approved or FDA-endorsed misbrands it, and Mintz says “clinically proven” claims would be off-limits. Sermorelin is the murky one. FDA withdrew its Geref approvals in 2009 at the maker’s request and determined in 2013 that the product was not pulled from sale for safety or effectiveness reasons. Sermorelin sits in no 503A category, and its compounding status is unsettled. Get counsel first.

Are peptides legal in sport and the military?

Legal to prescribe and allowed in competition are separate questions. WADA’s 2026 Prohibited List bans BPC-157 at all times under S0, the class for substances no government health authority has approved for human use. It also bans TB-500, CJC-1295, sermorelin, ipamorelin, AOD-9604, MOTS-c, insulins and tesamorelin, an FDA-approved drug. USADA and the NCAA list BPC-157 as banned too. A 503A listing is not FDA approval, so BPC-157 would stay under S0 even if FDA lists it.

The military keeps its own list. The Defense Department’s prohibited ingredients list includes BPC-157, which DoD calls “an unapproved drug” that “cannot be legally prescribed or sold over the counter,” and it prohibits peptide hormones such as GHRPs, sermorelin and ipamorelin for service members.

What happens next: a realistic timeline

To make the six compoundable, FDA has to accept the recommendations, publish a proposed rule, take comment (typically 60 to 90 days) and issue a final rule. Orrick says that process cannot be bypassed entirely, and the only alternative is Congress. FDA can also say no, which STAT calls unusual but not unprecedented.

History favors the long end. The first 503A bulks list took about four years, and a 2019 proposal to add five substances is still not final. The interim step to watch is enforcement discretion, which would not by itself make compounding legal: McDermott says Kennedy could place the peptides in Category 1 before a final rule, and Scott Brunner of the Alliance for Pharmacy Compounding told CNN that step is “possible, maybe even likely” if FDA accepts the recommendations. Nothing of the kind had been announced as of September 26.

Our planning assumption: no change in the law in 2026, a proposed rule as the first real signal, and final access in 2027 at the earliest. The next committee meeting, on LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF, is due before the end of February 2027 with no date set. If FDA does list the six, licensed pharmacies could compound them on prescription and clinicians could prescribe beyond the reviewed uses (NPR). They would not become FDA-approved or legal to sell as research chemicals, and Mintz notes a final rule could face a challenge under the Administrative Procedure Act.

What this means for telehealth operators

A compliant peptide program has three parts: a prescriber licensed in the patient’s state, a product with a lawful pathway, and a licensed pharmacy that can legally fill it. Today that means approved drugs, compounded preparations only where the ingredient clears 503A or 503B, and nothing from a research-chemical supplier. Consent forms do not fix a bad ingredient; Alabama and Mississippi said so in writing. If you want the six recommended peptides on the menu later, build the program now and add them after a final rule lands, or after counsel has reviewed any interim FDA enforcement policy against your states’ rules.

Remedora is a telehealth platform that brands use to launch with licensed providers, e-prescribing and pharmacy fulfillment. Read the telehealth platform overview, or book a Remedora demo to talk through your launch.

FAQ

Is BPC-157 legal in 2026?

Not for human use. BPC-157 is not FDA-approved and, as of September 26, 2026, cannot be lawfully compounded. The advisory committee recommended it 8-6-1 in July, but FDA has not proposed a rule. WADA and the Defense Department both ban it.

What peptides are FDA approved?

The main ones are semaglutide, tirzepatide, liraglutide, tesamorelin, bremelanotide, teriparatide, octreotide, leuprolide and oxytocin, each available by prescription and FDA-approved for the uses on its label. BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax are not approved.

Are peptides legal to buy online?

Yes, through a licensed telehealth provider and pharmacy, with a valid prescription for an approved or lawfully compounded drug. “Research use only” sites sell unapproved drugs, and FDA tells consumers not to buy research-labeled GLP-1s.

Is it legal to sell peptides in the US?

Peptide drugs for human use can be sold legally only as FDA-approved or lawfully compounded drugs, dispensed by a licensed pharmacy on a valid prescription. Food ingredients such as collagen peptides fall under separate rules. Selling peptides for human use under a research-only label violates the FD&C Act. In July 2026, two sellers whose catalogs included research-labeled peptides drew federal prison terms of 21 and 70 months.

Did the FDA ban peptides, or lift the ban?

Neither. FDA flagged several peptides as Category 2 safety risks in 2023, removed 12 from Category 2 in April 2026, and its advisory committee recommended six in July. None of that made them legal to compound, and FDA has not proposed a rule.

Was there FDA guidance on compounding peptides in February 2026?

Not formal guidance. The February 2026 news was political: on February 27, HHS Secretary Robert F. Kennedy Jr. told Joe Rogan he was a “big fan” of peptides and indicated about 14 of 19 restricted peptides could become more accessible. FDA followed on April 15 by removing 12 peptides from Category 2, which did not make them legal to compound. Separately, on February 6, FDA announced action against mass-marketed compounded GLP-1 drugs.

Did FDA send warning letters to peptide sellers in November 2025?

The big 2025 wave came earlier. On September 9, 2025, FDA sent more than 50 warning letters to companies compounding or manufacturing semaglutide and tirzepatide, mostly over claims that compounded versions are generic or the same as approved drugs. A November 2025 review of one seller’s website led to a December 12, 2025 letter to Pinnacle Peptides, but that letter concerned SARMs, not peptides. In 2026, FDA warned Gram Peptides and Mile High Compounds on March 31, Wholesale Peptide on June 17, and five online sellers on August 24.

When will the six recommended peptides be legal to compound?

Published estimates run from 8 to 12 months to two to four years or longer. A faster interim step would be FDA enforcement discretion, such as a Category 1 placement. That would not by itself make compounding legal, and none had been announced as of September 26, 2026.

Related Remedora guides

If you are mapping the rest of the launch, read the telehealth platform overview, e-prescribing and pharmacy fulfillment, choosing a HIPAA-compliant telehealth platform, and how to launch a telehealth company. Together they cover the clinical, pharmacy and compliance layers a peptide brand has to get right before the first ad dollar.